In the quest to outshine the broader market, stock pickers diligently seek out stocks with the potential for superior performance. Making the right choices can significantly elevate your wealth.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
After finishing at $0.25 in the prior trading day, Ginkgo Bioworks Holdings Inc (NYSE: DNA) closed at $0.22, down -13.00%. In other words, the price has decreased by -$13.00 from its previous closing price. On the day, 73.83 million shares were traded. DNA stock price reached its highest trading level at $0.249 during the session, while it also had its lowest trading level at $0.21.
Ratios:
Our goal is to gain a better understanding of DNA by taking a closer look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 4.71 and its Current Ratio is at 4.71. In the meantime, Its Debt-to-Equity ratio is 0.54 whereas as Long-Term Debt/Eq ratio is at 0.54.
Raymond James Downgraded its Outperform to Mkt Perform on November 14, 2023, whereas the target price for the stock was revised from $3.50 to $2.50.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Aug 16 ’24 when Che Austin bought 3,968 shares for $0.25 per share.
Che Austin bought 3,968 shares of DNA for $932 on Aug 15 ’24. On Aug 14 ’24, another insider, Che Austin, who serves as the Officer of the company, bought 3,968 shares for $0.28 each.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, DNA now has a Market Capitalization of 492398912 and an Enterprise Value of 182338240. For the stock, the TTM Price-to-Sale (P/S) ratio is 2.53 while its Price-to-Book (P/B) ratio in mrq is 0.52. Its current Enterprise Value per Revenue stands at 0.989 whereas that against EBITDA is -0.288.
Stock Price History:
Over the past 52 weeks, DNA has reached a high of $2.46, while it has fallen to a 52-week low of $0.22. The 50-Day Moving Average of the stock is -37.42%, while the 200-Day Moving Average is calculated to be -77.88%.
Shares Statistics:
The stock has traded on average 55.32M shares per day over the past 3-months and 45766270 shares per day over the last 10 days, according to various share statistics. A total of 1.53B shares are outstanding, with a floating share count of 1.42B. Insiders hold about 32.55% of the company’s shares, while institutions hold 44.87% stake in the company. Shares short for DNA as of 1722384000 were 123460989 with a Short Ratio of 2.23, compared to 1719532800 on 121104580. Therefore, it implies a Short% of Shares Outstanding of 123460989 and a Short% of Float of 9.8500006.
